Company Information
UCB
Prospects to 2010
| Publication Date | November 2008 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 80 |
| ISBN Number | not applicable |
| Product Code | ESP00160 |
Price
approximately: $901 | €664
Order above formats by FAX
Summary
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
UCB is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of CNS disorders, allergy/respiratory diseases, immune and inflammatory disorders, plus oncology. Headquartered in Brussels, Belgium, it has over 12,000 employees worldwide.
The Group has production and packaging facilities in Belgium, Switzerland, the US, Japan, Germany, India, Italy, Spain and South Korea and sells in more than 40 countries on all continents. During 2005, the Group disposed of the Surface Specialties business segment and transformed itself into a pure biopharmaceutical company. The recent acquisitions of Celltech and Schwarz Pharma should help establish UCB as one the leading biopharmaceutical companies in Europe.
UCB's current top-selling product is Keppra, a leading epilepsy therapy, which has recorded peak sales of over EUR 1 billion prior to patent expiry in 2009. The loss of patent protection is expected to heavily impact sales and prior to the acquisition of Schwarz, it appeared UCB would not have the resources to offset these losses. However, UCB now sells Schwarz-developed Neupro, a novel Parkinson's disease treatment recently approved in the US and Europe. Sales of Neupro are forecast to reach EUR 257 million in 2012, and combined with launches and sales for promising late-stage pipeline products such as Cimzia and Vimpat, the impact of falling sales of Keppra is expected to be considerably dampened.
Nonetheless, long-term growth remains threatened by this patent loss and UCB will have to make significant investment in R&D and seek to in-licence new products to further expand the product portfolio. The acquisition of Schwarz brings with it substantial expertise and research infrastructure in the field of biotechnology and in particular the treatment of CNS disorders. Consequently, UCB now has the tools required to overcome the difficulties anticipated with Keppra and to further re-enforce its position as one of the leading biopharmaceutical companies in Europe.
Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Acquisitions
- Divestitures
- Key Agreements
- Production
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D projects
- Conclusions/Outlook
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- CENTRAL NERVOUS SYSTEM
- Marketed Products
- Keppra
- Metadate CD/Equasym XL
- Neupro
- Vimpat
- Others
- R&D Projects
- Rikelta
- Growth Forecast
- IMMUNO-ALLERGOLOGY
- Marketed Products
- Cimzia
- Xyzal/Xusal
- Zyrtec/Reactine
- Others
- R&D Projects
- CDP323
- Epratuzumab
- Growth Forecast
- ONCOLOGY
- R&D Projects
- CDP791
- CMC544
- OTHERS
- Marketed Products
- Tussionex
- Others
- R&D Projects
- CDP7851
- APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2007
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Actelion Ltd
- Alembic Limited
- Amgen
- AstraZeneca
- Biogen Idec Inc
- BioInvent International AB
- BioWa Inc
- Immunomedics Inc
- Lonza Biologics Ltd
- Merck & Co
- Nektar Therapeutics
- Orphan Medical Inc
- Otsuka
- Pfizer
- sanofi-aventis
- Sepracor Inc
- Teva Pharmaceutical Industries Inc
- Verus Pharmaceuticals Inc
- APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDIX 6 - PRODUCT INDEX
- Index of Tables
- Principal Operating Results
- Royalty Income
- Net Pharmaceutical Sales By Geographical Area
- Net Sales By Geographical Area, 2007
- Recent Product Approvals
- Sales Of Major Biopharmaceutical Products
- Major CNS Products, 2007
- Major Immuno-allergology Products, 2007
- Major Other Products, 2007
- Index of Charts
- Royalty Income, 2007
- Sales of Top Ten Products (2003A-2013E)
- Top Selling Products, 2007
- Keppra Sales (2002A-2012E)
- Metadate Sales (2004A-2012E)
- Neupro Sales (2006A-2012E)
- Vimpat Sales (2008E-2012E)
- Bivaracetam Sales (2009E-2013E)
- Cimzia Sales (2008E-2012E)
- Xyzal Sales (2004A-2012E)
- Zyrtec Sales (2002A-2012E)
- Epratuzumab Sales (2009E-2013E)
- Tussionex Sales (2004A-2012E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
